Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.25.
Several equities analysts have commented on DOVA shares. Jefferies Group increased their price target on shares of Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. BidaskClub lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Finally, Evercore ISI started coverage on shares of Dova Pharmaceuticals in a research note on Friday, March 23rd. They issued a “line” rating and a $29.00 price target on the stock.
Shares of Dova Pharmaceuticals (NASDAQ DOVA) traded down $0.24 during trading hours on Friday, reaching $26.80. 83,622 shares of the company traded hands, compared to its average volume of 134,882. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.36). During the same quarter last year, the firm posted ($0.44) earnings per share. equities analysts forecast that Dova Pharmaceuticals will post -1.45 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its stake in Dova Pharmaceuticals by 702.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after purchasing an additional 4,163 shares during the last quarter. California State Teachers Retirement System purchased a new position in Dova Pharmaceuticals in the third quarter valued at approximately $202,000. Schwab Charles Investment Management Inc. purchased a new position in Dova Pharmaceuticals in the third quarter valued at approximately $241,000. Virtus Fund Advisers LLC purchased a new position in Dova Pharmaceuticals in the fourth quarter valued at approximately $318,000. Finally, Deutsche Bank AG increased its stake in Dova Pharmaceuticals by 139.2% in the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock valued at $337,000 after purchasing an additional 6,836 shares during the last quarter. Institutional investors own 26.05% of the company’s stock.
WARNING: “Dova Pharmaceuticals Inc (DOVA) Given Average Rating of “Buy” by Brokerages” was published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://macondaily.com/2018/04/12/dova-pharmaceuticals-inc-dova-given-average-rating-of-buy-by-brokerages-updated-updated.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.